The Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG) provides the only coordinated clinical trials research strategy for intensive care medicine in Australia and one of the few in the world. Its core business is the design and conduct of world-class multi-centre randomised controlled trials. It is clear that a national methods centre providing dedicated epidemiology, database and statistical expertise, together with improved infrastructure to support large cli ....The Australian and New Zealand Intensive Care Society Clinical Trials Group (ANZICS CTG) provides the only coordinated clinical trials research strategy for intensive care medicine in Australia and one of the few in the world. Its core business is the design and conduct of world-class multi-centre randomised controlled trials. It is clear that a national methods centre providing dedicated epidemiology, database and statistical expertise, together with improved infrastructure to support large clinical trials, will ensure the future of the group and enable greater productivity.Read moreRead less
The Breast Cancer Biospecimen Resource will consist of stored samples of the majority of newly diagnosed breast cancers in NSW and through the Australian and New Zealand Breast Cancer Trials Group together with accurate, prospectively tracked clinical data on each specimen. This facility will serve as a model for extension of similar procedures to other common Australian cancers including cancers of the lung, bowel, prostate and melanoma. Research that is facilitated by this Resource holds real ....The Breast Cancer Biospecimen Resource will consist of stored samples of the majority of newly diagnosed breast cancers in NSW and through the Australian and New Zealand Breast Cancer Trials Group together with accurate, prospectively tracked clinical data on each specimen. This facility will serve as a model for extension of similar procedures to other common Australian cancers including cancers of the lung, bowel, prostate and melanoma. Research that is facilitated by this Resource holds real promise for improving patient selection for treatment. This will return a significant humanitarian and cost saving benefit. In addition this advance would also maximise the benefit of population mammographic screening.Read moreRead less